1432630-26-6 Usage
Description
(S)-(((1-(6-aMino-9H-purin-9-yl)propan-2-yloxy)Methyl)phosphoryl)bis(oxy)bis(Methylene) isopropyl dicarbonate fuMarate, also known as Tenofovir Disoproxil USP Related Compound A, is an S-enantiomeric impurity of the antiviral drug Tenofovir Disoproxil Fumarate (TDF). TDF is an acyclic phosphonate nucleotide analogue and a potent reverse transcriptase inhibitor, widely used as an anti-HIV agent. The compound exhibits significant antiviral activity and plays a crucial role in the treatment of HIV/AIDS.
Uses
Used in Pharmaceutical Industry:
(S)-(((1-(6-aMino-9H-purin-9-yl)propan-2-yloxy)Methyl)phosphoryl)bis(oxy)bis(Methylene) isopropyl dicarbonate fuMarate is used as an impurity reference substance for the development and quality control of Tenofovir Disoproxil Fumarate, an anti-HIV drug. Its presence in the drug formulation is essential for ensuring the safety, efficacy, and quality of the final product.
Used in Antiviral Research:
In the field of antiviral research, this compound serves as a valuable reference for understanding the structure-activity relationship of Tenofovir Disoproxil Fumarate and its analogs. This knowledge aids in the design and development of novel antiviral agents with improved potency, selectivity, and reduced side effects.
Used in Quality Control and Regulatory Compliance:
(S)-(((1-(6-aMino-9H-purin-9-yl)propan-2-yloxy)Methyl)phosphoryl)bis(oxy)bis(Methylene) isopropyl dicarbonate fuMarate is utilized in the quality control processes of pharmaceutical manufacturers to ensure that the Tenofovir Disoproxil Fumarate drug meets the required standards and regulatory guidelines. This helps maintain the safety and efficacy of the drug for patients.
Used in Drug Development and Optimization:
(S)-(((1-(6-aMino-9H-purin-9-yl)propan-2-yloxy)Methyl)phosphoryl)bis(oxy)bis(Methylene) isopropyl dicarbonate fuMarate is employed in drug development and optimization studies, where researchers investigate its properties and interactions with biological targets. This information can be used to improve the design of new antiviral drugs, potentially leading to more effective treatments for HIV/AIDS and other viral infections.
Check Digit Verification of cas no
The CAS Registry Mumber 1432630-26-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,3,2,6,3 and 0 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1432630-26:
(9*1)+(8*4)+(7*3)+(6*2)+(5*6)+(4*3)+(3*0)+(2*2)+(1*6)=126
126 % 10 = 6
So 1432630-26-6 is a valid CAS Registry Number.
1432630-26-6Relevant articles and documents
METHODS FOR IMPROVING PURITY OF TENOFOVIR DISOPROXIL FUMARATE, AND COMPOSITIONS THEREOF
-
Paragraph 0189; 0197; 0199; 0201; 0203; 0205;0207, (2020/07/16)
Methods for producing tenofovir disoproxil fumarate with improved purity are provided. In particular, methods for producing tenofovir disoproxil fumarate with reduced levels of chloromethyl isopropyl carbonate are described. Also described are compositions containing tenofovir disoproxil fumarate with improved purity, and an analysis method that can be used to determine the purity of such compositions with improved accuracy and sensitivity.
Amorphous semi-tenoforvirdisoproxilfumarate tablet and preparation method thereof
-
Paragraph 0054; 0059-0061, (2019/11/12)
The invention relates to the technical field of medicine and discloses an amorphous semi-tenoforvirdisoproxilfumarate tablet and a preparation method thereof. The amorphous semi-tenoforvirdisoproxilfumarate tablet is prepared from, by weight, 35-60 parts of amorphous semi-tenoforvirdisoproxilfumarate, 30-60 parts of a filler, 2-10 parts of a disintegrating agent, 3-8 parts of a binding agent and 0.1-2 parts of a lubricating agent. The amorphous semi-tenoforvirdisoproxilfumarate is taken as the raw material drug, and the tablet obtained on the basis of not adopting special auxiliary materials and equipment has good stability and is not easy to degrade; wet particles are dried through a fluidized bed, and high efficiency, simple operation and good particle fluidity are achieved; the entire process is good in stability, and related substances, crystal forms and the like do not change and are good in stability in the long-term storage process; simple process and good economic benefit are achieved.
Preparation method of tenofovir disoproxil hemifumarate
-
Paragraph 0050; 0054-0056; 0060-0062; 0066-0067; 0076-0077, (2020/01/11)
The invention provides a preparation method of tenofovir disoproxil hemifumarate, particularly a preparation method of tenofovir disoproxil hemifumarate in a one-pot manner. Through adding a water-binding agent, generation of impurities in a synthesis process of tenofovir disoproxil is controlled, and therefore, the intermediate tenofovir disoproxil does not need to be completely separated from the reaction system, reaction treatment steps are saved, the loss of the process is reduced, the purity of the prepared tenofovir disoproxil hemifumarate is greater than 99.0%, and the impurity tenofovir monosoproxil is less than 0.1%; and the total molar yield is stabilized at 77%-85%.
